Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ersodetug in Tumor Hyperinsulinism
NCT06881992Phase 3Recruiting
- Sponsor
- Rezolute, Inc.
- Start
- Apr 2025
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of ersodetug in insulinoma, sponsored by Rezolute, Inc.. Started Apr 2025; status: recruiting.
02
Drugs
ersodetug
03
Conditions
insulinoma
Beyond the preview
Go deeper on NCT06881992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06881992.